JP2005512569A - 目的とする細胞指向性をもつウイルスクローンの同定に有用な修飾した構造遺伝子またはキャプシド修飾した粒子のライブラリー - Google Patents
目的とする細胞指向性をもつウイルスクローンの同定に有用な修飾した構造遺伝子またはキャプシド修飾した粒子のライブラリー Download PDFInfo
- Publication number
- JP2005512569A JP2005512569A JP2003554898A JP2003554898A JP2005512569A JP 2005512569 A JP2005512569 A JP 2005512569A JP 2003554898 A JP2003554898 A JP 2003554898A JP 2003554898 A JP2003554898 A JP 2003554898A JP 2005512569 A JP2005512569 A JP 2005512569A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- sequence
- library
- gene
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34413101P | 2001-12-21 | 2001-12-21 | |
| US36234902P | 2002-03-07 | 2002-03-07 | |
| US40711602P | 2002-08-30 | 2002-08-30 | |
| PCT/EP2002/014750 WO2003054197A2 (en) | 2001-12-21 | 2002-12-23 | A library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005512569A true JP2005512569A (ja) | 2005-05-12 |
| JP2005512569A5 JP2005512569A5 (enExample) | 2006-03-02 |
Family
ID=27407597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003554898A Pending JP2005512569A (ja) | 2001-12-21 | 2002-12-23 | 目的とする細胞指向性をもつウイルスクローンの同定に有用な修飾した構造遺伝子またはキャプシド修飾した粒子のライブラリー |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050106558A1 (enExample) |
| EP (2) | EP1456383B1 (enExample) |
| JP (1) | JP2005512569A (enExample) |
| AU (2) | AU2002352261B2 (enExample) |
| CA (1) | CA2468882C (enExample) |
| ES (1) | ES2467156T3 (enExample) |
| WO (1) | WO2003054197A2 (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010530737A (ja) * | 2007-05-31 | 2010-09-16 | メディジーン アーゲー | ワクチンとしての変異型パルボウイルス構造タンパク質 |
| WO2014103957A1 (ja) * | 2012-12-25 | 2014-07-03 | タカラバイオ株式会社 | Aav変異体 |
| JP2019518458A (ja) * | 2016-05-13 | 2019-07-04 | 4ディー モレキュラー セラピューティクス インコーポレイテッド | アデノ関連ウイルス変異キャプシドおよびその使用方法 |
| JP2021521833A (ja) * | 2018-04-27 | 2021-08-30 | ウニベルジテート ハイデルベルク | 筋疾患の治療のための改変aavカプシドポリペプチド |
| JP2022551986A (ja) * | 2019-10-16 | 2022-12-14 | ザ・ブロード・インスティテュート・インコーポレイテッド | 修飾筋肉標的化組成物 |
| JP2024056895A (ja) * | 2016-08-18 | 2024-04-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | モジュラーAAV送達システムによるCRISPR-Casゲノム編集 |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19827457C1 (de) * | 1998-06-19 | 2000-03-02 | Medigene Ag | Strukturprotein von AAV, seine Herstellung und Verwendung |
| US20070172460A1 (en) * | 2003-03-19 | 2007-07-26 | Jurgen Kleinschmidt | Random peptide library displayed on aav vectors |
| EP1486567A1 (en) * | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
| US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| WO2007084773A2 (en) * | 2006-01-20 | 2007-07-26 | University Of North Carolina At Chapel Hill | Enhanced production of infectious parvovirus vectors in insect cells |
| CN101511373B (zh) * | 2006-06-19 | 2015-12-09 | 阿斯克肋匹奥生物制药公司 | 用于基因治疗的修饰的因子ⅷ和因子ⅸ基因和载体 |
| EP2158211B1 (en) * | 2007-05-31 | 2016-08-10 | Medigene AG | Mutated structural protein of a parvovirus |
| EP2098536A1 (en) * | 2008-03-05 | 2009-09-09 | 4-Antibody AG | Isolation and identification of antigen- or ligand-specific binding proteins |
| EP2396343B1 (en) | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| JP5765790B2 (ja) * | 2010-10-21 | 2015-08-19 | ドイッチェス・クレープスフォルシュングスツェントルムDeutsches Krebsforschungszentrum | ラットパルボウイルスh−1pvのそのカプシドの遺伝子操作による癌細胞への再標的化 |
| DK3693025T3 (da) | 2011-04-22 | 2022-01-10 | Univ California | Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf |
| US9821043B2 (en) | 2011-09-15 | 2017-11-21 | Medigene Ag | Anti-HER2 vaccine based upon AAV derived multimeric structures |
| EP2692731A1 (en) * | 2012-07-31 | 2014-02-05 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Recombinant Adeno-Associated virus (AAV) vector particles displaying high-affinity ligands for cell-type specific gene delivery |
| US11136557B2 (en) | 2013-05-31 | 2021-10-05 | The Regents Of The University Of California | Adeno-associated virus variants and methods of use thereof |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| ES2822551T3 (es) | 2014-03-17 | 2021-05-04 | Adverum Biotechnologies Inc | Composiciones y métodos para la expresión génica mejorada en células de los conos |
| EP3221456B1 (en) * | 2014-11-21 | 2021-09-22 | University of Florida Research Foundation, Inc. | Genome-modified recombinant adeno-associated virus vectors |
| FI3265178T3 (fi) | 2015-03-02 | 2026-08-03 | Adverum Biotechnologies Inc | Koostumuksia ja menetelmiä polynukleotidien viemiseksi intravitreaalisesti retinaalisiin tappisoluihin |
| JP6836999B2 (ja) | 2015-03-24 | 2021-03-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | アデノ随伴ウイルス変異体及びその使用方法 |
| CN109640949B (zh) | 2016-07-29 | 2022-11-25 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体和其使用方法 |
| AU2017345470B2 (en) | 2016-10-19 | 2023-08-03 | Adverum Biotechnologies, Inc. | Modified AAV capsids and uses thereof |
| KR20250023600A (ko) | 2017-06-30 | 2025-02-18 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 변이체 캡시드를 보유한 아데노-부속 바이러스 비리온 및 이의 사용 방법 |
| MX2020001997A (es) | 2017-08-28 | 2020-07-20 | Univ California | Variantes de capside de virus adenoasociado y metodos de uso de estas. |
| DK3684423T5 (da) | 2017-09-20 | 2024-08-26 | 4D Molecular Therapeutics Inc | Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf |
| WO2019084015A1 (en) * | 2017-10-23 | 2019-05-02 | Daniel Schmidt | PROGRAMMABLE SET OF VIRUS COMPOSITES FOR ADMINISTRATION OF GENES TARGETING A RECEPTOR |
| US11766489B2 (en) | 2017-11-27 | 2023-09-26 | 4D Molecular Therapeutics, Inc. | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |
| EP3931335A2 (en) | 2019-02-25 | 2022-01-05 | Novartis AG | Compositions and methods to treat bietti crystalline dystrophy |
| US20220154210A1 (en) | 2019-02-25 | 2022-05-19 | Novartis Ag | Compositions and methods to treat bietti crystalline dystrophy |
| EP3715358A1 (en) | 2019-03-28 | 2020-09-30 | Universität zu Köln | Mutated adeno-associated virus capsid proteins, aav particle comprising the same and liver directed aav vector gene therapy |
| CN114269926A (zh) | 2019-04-26 | 2022-04-01 | 美商圣加莫治疗股份有限公司 | Aav工程化 |
| CN119317718A (zh) | 2022-01-25 | 2025-01-14 | 宾夕法尼亚州大学信托人 | 用于改善心脏转导和肝脏去靶向的aav衣壳 |
| WO2025102034A1 (en) | 2023-11-10 | 2025-05-15 | The Trustees Of The University Of Pennsylvania | Gene therapy for barth syndrome |
| WO2026122921A1 (en) | 2024-12-05 | 2026-06-11 | The Trustees Of The University Of Pennsylvania | Gene therapy for barth syndrome |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6031071A (en) * | 1996-01-24 | 2000-02-29 | Biophage, Inc. | Methods of generating novel peptides |
| WO1997038723A1 (en) * | 1996-04-16 | 1997-10-23 | Immusol Incorporated | Targeted viral vectors |
| ATE291633T1 (de) * | 1999-06-01 | 2005-04-15 | Univ Washington | Rekombinante adenovirale vektoren, die chimäre fiberproteine exprimieren, für die zellspezifische infektion und genomische integration |
| WO2002053703A2 (en) * | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
-
2002
- 2002-12-23 US US10/498,163 patent/US20050106558A1/en not_active Abandoned
- 2002-12-23 AU AU2002352261A patent/AU2002352261B2/en not_active Expired
- 2002-12-23 JP JP2003554898A patent/JP2005512569A/ja active Pending
- 2002-12-23 WO PCT/EP2002/014750 patent/WO2003054197A2/en not_active Ceased
- 2002-12-23 ES ES02787962.6T patent/ES2467156T3/es not_active Expired - Lifetime
- 2002-12-23 EP EP02787962.6A patent/EP1456383B1/en not_active Expired - Lifetime
- 2002-12-23 EP EP10011286A patent/EP2363487A3/en not_active Withdrawn
- 2002-12-23 CA CA2468882A patent/CA2468882C/en not_active Expired - Lifetime
-
2008
- 2008-05-07 AU AU2008202032A patent/AU2008202032B2/en not_active Expired
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010530737A (ja) * | 2007-05-31 | 2010-09-16 | メディジーン アーゲー | ワクチンとしての変異型パルボウイルス構造タンパク質 |
| JP2015121536A (ja) * | 2007-05-31 | 2015-07-02 | メディジーン アーゲー | ワクチンとしての変異型パルボウイルス構造タンパク質 |
| JP2018109636A (ja) * | 2007-05-31 | 2018-07-12 | メディジーン アーゲー | ワクチンとしての変異型パルボウイルス構造タンパク質 |
| WO2014103957A1 (ja) * | 2012-12-25 | 2014-07-03 | タカラバイオ株式会社 | Aav変異体 |
| JPWO2014103957A1 (ja) * | 2012-12-25 | 2017-01-12 | タカラバイオ株式会社 | Aav変異体 |
| US11364308B2 (en) | 2016-05-13 | 2022-06-21 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and methods of use thereof |
| US11167041B2 (en) | 2016-05-13 | 2021-11-09 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and methods of use thereof |
| US11179477B2 (en) | 2016-05-13 | 2021-11-23 | 4D Molecular Therapeutics Inc. | Method of using adeno-associated virus with variant capsid |
| JP2019518458A (ja) * | 2016-05-13 | 2019-07-04 | 4ディー モレキュラー セラピューティクス インコーポレイテッド | アデノ関連ウイルス変異キャプシドおよびその使用方法 |
| US11419949B2 (en) | 2016-05-13 | 2022-08-23 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and methods of use thereof |
| JP2024056895A (ja) * | 2016-08-18 | 2024-04-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | モジュラーAAV送達システムによるCRISPR-Casゲノム編集 |
| JP2021521833A (ja) * | 2018-04-27 | 2021-08-30 | ウニベルジテート ハイデルベルク | 筋疾患の治療のための改変aavカプシドポリペプチド |
| JP2022551986A (ja) * | 2019-10-16 | 2022-12-14 | ザ・ブロード・インスティテュート・インコーポレイテッド | 修飾筋肉標的化組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003054197A3 (en) | 2004-03-18 |
| CA2468882A1 (en) | 2003-07-03 |
| AU2008202032A1 (en) | 2009-11-26 |
| CA2468882C (en) | 2015-09-29 |
| AU2002352261A1 (en) | 2003-07-09 |
| WO2003054197A2 (en) | 2003-07-03 |
| ES2467156T3 (es) | 2014-06-12 |
| EP1456383A2 (en) | 2004-09-15 |
| EP1456383B1 (en) | 2014-03-12 |
| EP2363487A3 (en) | 2012-03-21 |
| US20050106558A1 (en) | 2005-05-19 |
| EP2363487A2 (en) | 2011-09-07 |
| AU2008202032B2 (en) | 2012-09-20 |
| AU2002352261B2 (en) | 2008-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002352261B2 (en) | A library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism | |
| JP7438981B2 (ja) | アデノ随伴ウイルスの肝臓特異的向性 | |
| US7749492B2 (en) | AAV vectors and methods | |
| US6962815B2 (en) | AAV2 vectors and methods | |
| CA2379220C (en) | Structural protein of adeno-associated virus with modified antigenicity, its production and its use | |
| JP4652570B2 (ja) | Aavの構造タンパク質、その製造及び用途 | |
| M Mitchell et al. | AAV's anatomy: roadmap for optimizing vectors for translational success | |
| US20040180440A1 (en) | Modified AAV | |
| KR20210144836A (ko) | 돌연변이된 아데노-연관 바이러스 캡시드 단백질, 이를 포함하는 aav 입자 및 간 특이적 aav 벡터 유전자 치료요법 | |
| US20150126588A1 (en) | Adeno associated virus plasmids and vectors | |
| KR20160131032A (ko) | 곤충 세포에서 생산된 더욱 향상된 aav 벡터 | |
| CN104937100A (zh) | Aav变体 | |
| JP2023540960A (ja) | 操作されたaavベクター | |
| WO2013159036A1 (en) | Adeno associated virus plasmids and vectors | |
| AU2013254897B2 (en) | Vectors with modified initiation codon for the translation of AAV-Rep78 useful for production of AAV in insect cells | |
| WO2025006957A2 (en) | Non-neutralizing aav constructs and methods of generating and using same | |
| Xu et al. | Capsid modification of adeno-associated virus and tumor targeting gene therapy | |
| WO2025051747A1 (en) | Viral vector for fibroblast transfection | |
| Wei et al. | 105. Use of a Recombinant Adenovirus Expressing the AAV-2 Rep52 Helicase To Enhance Vector Potency from Stable rAAV Producer Cell Lines | |
| AU2016202153A1 (en) | Vectors with modified initiation codon for the translation of AAV-Rep78 useful for production of AAV in insect cells | |
| HK1215277B (en) | Aav variant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051226 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051226 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080903 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20081203 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091014 |